Taymeyah Al-Toubah is an expert in Oncology at Moffitt Cancer Center (United States). Taymeyah Al-Toubah has authored 66 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 291 (community average: 125). How the SLR is computed.

LeadR Profile

Taymeyah Al-Toubah Moffitt Cancer Center United States
291 ScienceLeadR Reputation 291
Network Map

Oncology

Subspecialties: Endocrinology - Nuclear Medicine - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2017 - 2026

Source: PubMed

Moffitt Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 66

Citations

Citations: 1 163 1st author: 29 Last author: 2 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Somatostatin Receptor Expression on [ 68Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study.
PMID 42276784 — cells, somatostatin, neoplasms, neoplasm metastasis, nuclear medicine, receptors, somatostatin, prospective studies, carcinoma, neuroendocrine
J Nucl Med20260
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
PMID 41182464 — dna mismatch repair, neoplasms, drug therapy, immunotherapy, neuroendocrine tumors, therapeutics, mutation, chemotherapy
Endocr Pathol20250
Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors.
PMID 41028638 — neoplasms, proton pump inhibitors, neuroendocrine tumors, therapeutics, proton pumps
Ann Surg Oncol20250
Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE.
PMID 40641634 — neoplasms, aftercare, neuroendocrine tumors, therapeutics, ischemia
Endocr Oncol20250
Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging.
PMID 40563587 — somatostatin, absenteeism, tomography, positron-emission tomography, neoplasms, fluorodeoxyglucose f18, neuroendocrine tumors, receptors, somatostatin
Cancers (Basel)20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 3

By status:

Completed 3

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 3
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map